UNSPSC 51113601: Irofulven

This classification denotes an antineoplastic alkylating agent with the molecular formula C15H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6B799IH05A, chemically known as spiro(cyclopropane-1,5(5h)-inden)-7(6h)-one, 6-hydroxy-3-(hydroxymethyl)-2,4,6-trimethyl-, (r)- but more generally known as irofulven, which bears U.S. National Institutes of Health Compound Identifier 148189. European Medicines Agency schedules Irofulven in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02773MIG.

UNSPSC 51113601 Irofulven, a Commodity code, covers pharmaceutical oncology agents—specifically the chemotherapy drug irofulven—that state and local health agencies procure through pharmacy benefit programs, direct-purchase arrangements, and therapeutic initiatives. The scope of work under this code reflects state health departments' and Medicaid programs' procurement of specific branded or generic cancer medications as part of formulary management, drug sourcing, and cost-containment initiatives. Issuing bodies soliciting under this code include state health and human services departments managing pharmacy benefits for Medicaid populations and state employee health plans, though the recent activity suggests that state procurement agencies are now exploring direct-to-manufacturer contracting models outside traditional pharmacy benefit manager and group purchasing organization channels.

The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a market-intelligence gathering phase designed to understand which vendors can establish direct contracts with state agencies and self-insured employee health plans for prescription fulfillment without intermediary PBMs or wholesalers. Texas represents the primary recent activity under this code, with no other state or local solicitations currently documented in the source. The RFI does not identify a formal contract award value, timeline, or set-asides; it functions as preliminary research to inform the state's subsequent formal procurement strategy and contracting structure for pharmaceutical sourcing.